Hemispherx Biopharma announced that an order of newly manufactured rintatolimod (Ampligen®) for sale utilizing the Early Access Program (EAP) in Europe has been shipped with receipt confirmed on January 26. In May 2016, the Company executed an amended and restated agreement with Impatients N.V., for the commencement and management of an Early Access Program (EAP) in all of Europe and Turkey.